A Cochrane meta-analysis has concluded that monoamine oxidase (MAO)-B inhibitors are a treatment option in early PD patients but appear to be somewhat less effective than levodopa or a dopamine agonist (Caslake et al. Cochrane Database Syst Rev 2009; Oct 7;(4): CD006661).